Positive News SentimentPositive NewsNASDAQ:STIM Neuronetics (STIM) Stock Price, News & Analysis $3.33 -0.11 (-3.20%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.33 0.00 (0.00%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Neuronetics Stock (NASDAQ:STIM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neuronetics alerts:Sign Up Key Stats Today's Range$3.18▼$3.4850-Day Range$3.20▼$4.6652-Week Range$0.52▼$5.92Volume1.47 million shsAverage Volume1.63 million shsMarket Capitalization$220.18 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company Overview Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. Read More Neuronetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreSTIM MarketRank™: Neuronetics scored higher than 38% of companies evaluated by MarketBeat, and ranked 736th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNeuronetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeuronetics has only been the subject of 1 research reports in the past 90 days.Read more about Neuronetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($1.13) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 6.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neuronetics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.87% of the float of Neuronetics has been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Neuronetics has recently increased by 0.85%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.87% of the float of Neuronetics has been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Neuronetics has recently increased by 0.85%, indicating that investor sentiment is decreasing. News and Social Media2.7 / 5News SentimentN/A News SentimentNeuronetics has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Neuronetics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for STIM on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.70% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neuronetics' insider trading history. Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STIM Stock News HeadlinesNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 6, 2025 | globenewswire.comNeuronetics, Inc. (NASDAQ:STIM) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | msn.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 30 at 2:00 AM | Brownstone Research (Ad)Neuronetics, Inc. (STIM) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comWhat To Expect From Neuronetics Inc (STIM) Q2 2025 EarningsAugust 5, 2025 | finance.yahoo.comNeuronetics to Present at the Canaccord Genuity 45th Annual Growth ConferenceAugust 4, 2025 | globenewswire.comNeuronetics Study Shows Strong Antidepressant Results for Teens and Young Adults Using NeuroStar TMSAugust 2, 2025 | msn.comNeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed AdolescentsJuly 30, 2025 | globenewswire.comSee More Headlines STIM Stock Analysis - Frequently Asked Questions How have STIM shares performed this year? Neuronetics' stock was trading at $1.61 at the start of the year. Since then, STIM shares have increased by 106.8% and is now trading at $3.33. How were Neuronetics' earnings last quarter? Neuronetics, Inc. (NASDAQ:STIM) posted its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.07. The company earned $38.11 million during the quarter, compared to analyst estimates of $36.80 million. Neuronetics had a negative net margin of 43.47% and a negative trailing twelve-month return on equity of 156.36%. Read the conference call transcript. When did Neuronetics IPO? Neuronetics (STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. Who are Neuronetics' major shareholders? Neuronetics' top institutional shareholders include Balyasny Asset Management L.P. (2.28%), Geode Capital Management LLC (1.33%), Boothbay Fund Management LLC (0.51%) and Massar Capital Management LP (0.33%). Insiders that own company stock include Cannell Capital Llc, Keith J Sullivan, William Andrew Macan, Robert Cascella, Stephen Furlong and Glenn P Muir. View institutional ownership trends. How do I buy shares of Neuronetics? Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neuronetics investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Pfizer (PFE), GE Aerospace (GE), Intel (INTC), Bank of America (BAC) and Nokia (NOK). Company Calendar Last Earnings8/05/2025Today8/30/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:STIM CIK1227636 Webwww.neurostar.com Phone(610) 640-4202Fax610-640-4206Employees180Year FoundedN/APrice Target and Rating Average Price Target for Neuronetics$7.00 High Price Target$7.00 Low Price Target$7.00 Potential Upside/Downside+110.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.71 million Net Margins-43.47% Pretax Margin-43.70% Return on Equity-156.36% Return on Assets-35.69% Debt Debt-to-Equity Ratio1.76 Current Ratio2.02 Quick Ratio1.84 Sales & Book Value Annual Sales$74.89 million Price / Sales2.94 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book6.94Miscellaneous Outstanding Shares66,120,000Free Float60,372,000Market Cap$220.18 million OptionableOptionable Beta1.78 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:STIM) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.